Cartron, Guillaume

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 940

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research

Immune Cell Function and InteractionMonoclonal and Polyclonal Antibodies Research

Cited by 434

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., et al. (2018) · New England Journal of Medicine

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 373

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells

Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., et al. (2016) · Blood

Immune cells in cancerLymphoma Diagnosis and Treatment

Cited by 168

Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production

Khan, A. U. H., Rathore, M. G., Allende-Vega, N., Vo, D.-N., Belkhala, S., Orecchioni, S., Talarico, G., Bertolini, F., Cartron, G., Lecellier, C.-H., et al. (2016) · EBioMedicine

Genomics, phytochemicals, and oxidative stressRedox biology and oxidative stress

Cited by 59

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide

Lodé, L., Ménard, A., Flet, L., Richebourg, S., Loirat, M., Eveillard, M., Le Bris, Y., Godon, C., Theisen, O., Gagez, A.-L., et al. (2018) · Haematologica

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 52

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Morschhauser, F., Bishton, M., Eyre, T. A., Bachy, E., Cartron, G., Ysebaert, L., Bobillo, S., Gutierrez, N. C., Budde, L. E., Fox, C. P., et al. (2021) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 46